Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 617

1.

Machine learning can identify newly diagnosed patients with CLL at high risk of infection.

Agius R, Brieghel C, Andersen MA, Pearson AT, Ledergerber B, Cozzi-Lepri A, Louzoun Y, Andersen CL, Bergstedt J, von Stemann JH, Jørgensen M, Tang ME, Fontes M, Bahlo J, Herling CD, Hallek M, Lundgren J, MacPherson CR, Larsen J, Niemann CU.

Nat Commun. 2020 Jan 17;11(1):363. doi: 10.1038/s41467-019-14225-8.

PMID:
31953409
2.

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

Fürstenau M, De Silva N, Eichhorst B, Hallek M.

Hemasphere. 2019 Aug 9;3(5):e287. doi: 10.1097/HS9.0000000000000287. eCollection 2019 Oct. Review.

3.

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG).

Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, Bloehdorn J, Hoechstetter M, Fischer K, Eichhorst B, Goede V, Hallek M, Döhner H, Rosenquist R, Ghia P, Stamatopoulos K, Stilgenbauer S.

Haematologica. 2019 Dec 26. pii: haematol.2019.231027. doi: 10.3324/haematol.2019.231027. [Epub ahead of print]

4.

Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis.

Rothe A, Claßen A, Carney J, Hallek M, Mellinghoff SC, Scheid C, Holtick U, von Bergwelt-Baildon M.

Eur J Haematol. 2019 Dec 19. doi: 10.1111/ejh.13372. [Epub ahead of print]

PMID:
31856310
5.

Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Eichhorst B, Fürstenau M, Hallek M.

Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):482-489. doi: 10.1182/hematology.2019000070.

PMID:
31808867
6.

Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy.

Fürstenau M, Hopfinger G, Robrecht S, Fink AM, Al-Sawaf O, Langerbeins P, Cramer P, Tresckow JV, Maurer C, Kutsch N, Hoechstetter M, Dreyling M, Lange E, Kneba M, Stilgenbauer S, Döhner H, Hensel M, Kiehl MG, Jaeger U, Wendtner CM, Goede V, Fischer K, von Bergwelt-Baildon M, Eichhorst B, Hallek M, Theurich S.

Leukemia. 2019 Nov 14. doi: 10.1038/s41375-019-0630-6. [Epub ahead of print] No abstract available.

PMID:
31728057
7.

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.).

Weiss J, Peifer M, Herling CD, Frenzel LP, Hallek M.

Haematologica. 2019 Nov;104(11):e540. doi: 10.3324/haematol.2019.232835. No abstract available.

8.

Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia.

Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0597-3. [Epub ahead of print] No abstract available.

PMID:
31611627
9.

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia.

Fürstenau M, Hallek M, Eichhorst B.

Haematologica. 2019 Nov;104(11):2144-2154. doi: 10.3324/haematol.2018.208603. Epub 2019 Oct 4. Review.

10.

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.

Lancet Oncol. 2019 Nov;20(11):1576-1586. doi: 10.1016/S1470-2045(19)30503-0. Epub 2019 Sep 30.

PMID:
31582354
11.

Exosome-dependent immune surveillance at the metastatic niche requires BAG6 and CBP/p300-dependent acetylation of p53.

Schuldner M, Dörsam B, Shatnyeva O, Reiners KS, Kubarenko A, Hansen HP, Finkernagel F, Roth K, Theurich S, Nist A, Stiewe T, Paschen A, Knittel G, Reinhardt HC, Müller R, Hallek M, von Strandmann EP.

Theranostics. 2019 Aug 14;9(21):6047-6062. doi: 10.7150/thno.36378. eCollection 2019.

12.

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription.

Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, Dolnik A, Blätte TJ, Landau DA, Saub J, Estenfelder S, Ibach S, Cymbalista F, Leblond V, Delmer A, Bahlo J, Robrecht S, Fischer K, Goede V, Bullinger L, Wu CJ, Mertens D, Ficz G, Gribben JG, Hallek M, Döhner H, Stilgenbauer S.

Haematologica. 2019 Aug 29. pii: haematol.2019.217307. doi: 10.3324/haematol.2019.217307. [Epub ahead of print]

13.

The economic burden of endoscopic treatment for anastomotic leaks following oncological Ivor Lewis esophagectomy.

Baltin C, Kron F, Urbanski A, Zander T, Kron A, Berlth F, Kleinert R, Hallek M, Hoelscher AH, Chon SH.

PLoS One. 2019 Aug 28;14(8):e0221406. doi: 10.1371/journal.pone.0221406. eCollection 2019.

14.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M.

Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):715-722.e6. doi: 10.1016/j.clml.2019.07.004. Epub 2019 Jul 15.

15.

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.

Kreuzer KA, Furman RR, Stilgenbauer S, Dubowy RL, Kim Y, Munugalavadla V, Lilienweiss E, Reinhardt HC, Cramer P, Eichhorst B, Hillmen P, O'Brien SM, Pettitt AR, Hallek M.

Leukemia. 2020 Jan;34(1):296-300. doi: 10.1038/s41375-019-0533-6. Epub 2019 Aug 19. No abstract available.

PMID:
31427720
16.

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.

Hallek M.

Am J Hematol. 2019 Nov;94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4.

PMID:
31364186
17.

Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, Newman AM, Dührsen U, Hüttmann A, Casasnovas O, Westin JR, Ritgen M, Böttcher S, Langerak AW, Roschewski M, Wilson WH, Gaidano G, Rossi D, Bahlo J, Hallek M, Tibshirani R, Diehn M, Alizadeh AA.

Cell. 2019 Jul 25;178(3):699-713.e19. doi: 10.1016/j.cell.2019.06.011. Epub 2019 Jul 4.

PMID:
31280963
18.

Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital.

Eichenauer DA, Golla H, Thielen I, Hallek M, Voltz R, Perrar KM.

Ann Hematol. 2019 Nov;98(11):2605-2607. doi: 10.1007/s00277-019-03748-1. Epub 2019 Jun 28. No abstract available.

PMID:
31253997
19.

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).

Al-Sawaf O, Bazeos A, Robrecht S, Bahlo J, Gower C, Fink AM, Tresckow J, Cramer P, Langerbeins P, Kutsch N, Humphrey K, Fingerle-Rowson G, Stilgenbauer S, Wendtner CM, Fischer K, Eichhorst B, Hallek M, Goede V.

Am J Hematol. 2019 Jun 20. doi: 10.1002/ajh.25561. [Epub ahead of print]

PMID:
31222797
20.

How to approach CLL in clinical practice.

Hallek M, Fürstenau M.

Hematol Oncol. 2019 Jun;37 Suppl 1:38-42. doi: 10.1002/hon.2583. Review. No abstract available.

PMID:
31187520
21.

FimH-based display of functional eukaryotic proteins on bacteria surfaces.

Chmielewski M, Kuehle J, Chrobok D, Riet N, Hallek M, Abken H.

Sci Rep. 2019 Jun 10;9(1):8410. doi: 10.1038/s41598-019-44883-z.

22.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M.

N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

PMID:
31166681
23.

Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials.

Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V, Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK, Eichhorst B, Hallek M.

Anticancer Res. 2019 May;39(5):2591-2598. doi: 10.21873/anticanres.13382.

PMID:
31092457
24.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

25.

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S.

J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17.

PMID:
30995176
26.

Extracellular vesicle measurements with nanoparticle tracking analysis - An accuracy and repeatability comparison between NanoSight NS300 and ZetaView.

Bachurski D, Schuldner M, Nguyen PH, Malz A, Reiners KS, Grenzi PC, Babatz F, Schauss AC, Hansen HP, Hallek M, Pogge von Strandmann E.

J Extracell Vesicles. 2019 Apr 1;8(1):1596016. doi: 10.1080/20013078.2019.1596016. eCollection 2019.

27.

Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.

Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S.

Leukemia. 2019 Sep;33(9):2183-2194. doi: 10.1038/s41375-019-0446-4. Epub 2019 Mar 25.

PMID:
30911113
28.

The Treatment of Chronic Lymphatic Leukemia.

Tresckow JV, Eichhorst B, Bahlo J, Hallek M.

Dtsch Arztebl Int. 2019 Jan 25;116(4):41-46. doi: 10.3238/arztebl.2019.0041. Review.

29.

Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity.

Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, Odenthal M, Adriouch S, Salvetti A, Büning H.

Sci Rep. 2019 Mar 6;9(1):3631. doi: 10.1038/s41598-019-40071-1.

30.

Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report.

Bühl L, Abel T, Wolf F, Oberste M, Bloch W, Hallek M, Elter T, Zimmer P.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419832358. doi: 10.1177/1534735419832358.

31.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

32.

Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience.

Ram R, Scheid C, Amit O, Chemnitz JM, Moshe Y, Hallek M, Wolf D, Avivi I, Holtick U.

Haematologica. 2019 Sep;104(9):1798-1803. doi: 10.3324/haematol.2018.203869. Epub 2019 Feb 7.

33.

New roles for B cell receptor associated kinases: when the B cell is not the target.

Nguyen PH, Niesen E, Hallek M.

Leukemia. 2019 Mar;33(3):576-587. doi: 10.1038/s41375-018-0366-8. Epub 2019 Jan 30. Review.

PMID:
30700840
34.

HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?

Drößler L, Lehmann C, Töpelt K, Nierhoff D, Vehreschild JJ, Rybniker J, Hallek M, Fischer J, Stormberg V, Fätkenheuer G, Wieland U, Jung N.

Infection. 2019 Apr;47(2):293-300. doi: 10.1007/s15010-019-01271-z. Epub 2019 Jan 28.

PMID:
30689161
35.

Early Palliative Care: Pro, but Please Be Precise!

Gärtner J, Daun M, Wolf J, von Bergwelt-Baildon M, Hallek M.

Oncol Res Treat. 2019;42(1-2):11-18. doi: 10.1159/000496184. Epub 2019 Jan 26. Review.

PMID:
30685764
36.

[Multiple myeloma].

Hallek M, Haller H.

Internist (Berl). 2019 Jan;60(1):1-2. doi: 10.1007/s00108-018-0553-8. German. No abstract available.

PMID:
30656394
37.

CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.

von Tresckow J, Cramer P, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Illmer T, Klaproth H, Estenfelder S, Ritgen M, Fischer K, Wendtner CM, Kreuzer KA, Stilgenbauer S, Böttcher S, Eichhorst BF, Hallek M.

Leukemia. 2019 May;33(5):1161-1172. doi: 10.1038/s41375-018-0313-8. Epub 2018 Dec 19.

PMID:
30568174
38.

Management of unfit elderly patients with chronic lymphocytic leukemia.

Eichhorst B, Hallek M, Goede V.

Eur J Intern Med. 2018 Dec;58:7-13. doi: 10.1016/j.ejim.2018.02.001. Review.

PMID:
30527922
39.

On the architecture of translational research designed to control chronic lymphocytic leukemia.

Hallek M.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8. doi: 10.1182/asheducation-2018.1.1. Review.

40.

Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment? - A Systematic Review.

Baumann FT, Reike A, Hallek M, Wiskemann J, Reimer V.

Breast Care (Basel). 2018 Oct;13(5):380-385. doi: 10.1159/000487428. Epub 2018 May 3. Review.

41.

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.

Al-Sawaf O, Bahlo J, Robrecht S, Fischer K, Herling CD, Hoechstetter M, Fink AM, von Tresckow J, Langerbeins P, Cramer P, Stilgenbauer S, Wendtner CM, Eichhorst B, Hallek M, Goede V.

Br J Haematol. 2018 Dec;183(5):727-735. doi: 10.1111/bjh.15604. Epub 2018 Nov 21.

PMID:
30460980
42.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19. No abstract available.

43.

Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.

Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD.

Leuk Lymphoma. 2019 Jun;60(6):1438-1446. doi: 10.1080/10428194.2018.1540782. Epub 2018 Nov 8.

PMID:
30407886
44.

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A.

Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12.

45.

Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.

Pasternack H, Fassunke J, Plum PS, Chon SH, Hescheler DA, Gassa A, Merkelbach-Bruse S, Bruns CJ, Perner S, Hallek M, Büttner R, Bollschweiler E, Hölscher AH, Quaas A, Zander T, Weiss J, Alakus H.

Sci Rep. 2018 Oct 8;8(1):14941. doi: 10.1038/s41598-018-33027-4.

46.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.

PMID:
30234404
47.

[The 2017/2018 influenza season-business as usual? : A statement of medical societies].

Kochanek M, Böll B, Shimabukuro-Vornhagen A, Welte T, Wieland U, Pletz M, Hallek M, Fätkenheuer G, Salzberger B.

Internist (Berl). 2018 Oct;59(10):1122-1124. doi: 10.1007/s00108-018-0501-7. German. No abstract available.

PMID:
30218201
48.

[Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)].

von Tresckow J, Hallek M, Eichhorst B.

Dtsch Med Wochenschr. 2018 Sep;143(18):1318-1324. doi: 10.1055/a-0550-2286. Epub 2018 Sep 10. German.

PMID:
30199912
49.

Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia.

Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C.

Biol Blood Marrow Transplant. 2019 Mar;25(3):488-495. doi: 10.1016/j.bbmt.2018.08.029. Epub 2018 Sep 5.

PMID:
30194027
50.

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.

Krause G, Hassenrück F, Hallek M.

Drug Des Devel Ther. 2018 Aug 21;12:2577-2590. doi: 10.2147/DDDT.S142406. eCollection 2018. Review.

Supplemental Content

Loading ...
Support Center